In this study, hydroxamate-based (<b>3a</b>) and benzamide-based (<b>6a</b>) HDAC inhibitors were synthesized and evaluated in glioma cell lines and glioblastoma stem cells (GSC). Here, HDAC9 is linked to glioblastoma.